Big Pharma trio backs cancer startup; AB jumps on ALS data; Shire founder oversees AIM listing

Nick Paul Taylor In this week's EuroBiotech Report, Metabomed celebrated adding Pfizer to a list of investors that already featured the VC units of Merck KGaA and Boehringer Ingelheim. ...

Does pharma need to get cracking on Instagram? New features could be the trigger

Tracy Staton Instagram's latest updates could help pharma companies get more out of using the social app. Longer videos, for instance, give more room for drugmakers to comply with ...

Big Pharma chalks up victory in Arizona Supreme Court over Rx safety warnings

Emily Wasserman Big Pharma can celebrate a bright point. Arizona's top court ruled that drugmakers don't have an obligation to warn patients directly about safety risks of their ...

Mapi Pharma swings for $50M haul as oft-delayed IPO nears D-Day

Nick Paul Taylor Mapi Pharma has set the terms for its latest crack at listing on Nasdaq. The biotech, which set terms on its first IPO attempt back in April 2014, is aiming to round ...

Indian pharma mulls deal for U.S. injectables maker Sagent Pharma

Emily Wasserman U.S. injectables maker Sagent Pharmaceuticals is considering putting itself on the chopping block, and if or when it does, at least 5 Indian drugmakers could come calling. FiercePharma ...

Levaquin users slap J&J with $800M RICO suit, claiming pharma giant hid serious side effects

Emily Wasserman Johnson & Johnson is facing yet another lawsuit over its antibiotic Levaquin from people who claim that the company hid serious side effects tied to the drug. The ...

U.K. competition watchdog targets pharma for ‘substantial fines’

Emily Wasserman The U.K.'s Competition and Markets Authority (CMA) is planning to levy "substantial fines" this year, marking a "big step up in the scale and impact" ...

FDA bans products from China plant used by Big Pharma players

Emily Wasserman A Chinese ingredient maker who has produced ingredients for some of the big guns in pharma including Novartis, Sanofi and Pfizer is getting its products banned by the ...

Theracos raises $25M to take on Big Pharma in diabetes

Damian Garde Marlborough, MA's Theracos raised $ 25 million to support its work on a safer version of a common treatment for Type 2 diabetes. FierceBiotech News

FTC stats show pharma backing off pay-for-delay deals after SCOTUS ruling

Tracy Staton For years, the Federal Trade Commission lamented the ever-growing number of pay-for-delay patent settlements–three in 2005, 14 in 2007, up to a record 40 in 2012–and ...

Pharma scandals spawn investor lawsuits at KaloBios, Sequoia

Carly Helfand Angry investors of KaloBios and Sequoia Fund are taking their pharma grievances to the courts. FiercePharma News

Sanofi commits €400M to another cancer R&D pact, this time with Innate Pharma

John Carroll Less than a year after Sanofi downsized its cancer drug R&D operations, the pharma giant has struck back-to-back deals to launch new immuno-oncology drug programs, ...
Page 1 of 1712345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS